Valuation: Novartis AG

Market Cap 293B 254B 238B 218B 411B 27,892B 416B 2,784B 1,092B 13,936B 1,099B 1,075B 46,385B P/E 2026 *
21.9x
P/E 2027 * 18.7x
Enterprise Value 326B 283B 265B 242B 457B 31,047B 463B 3,098B 1,216B 15,512B 1,224B 1,197B 51,630B EV / Sales 2026 *
5.66x
EV / Sales 2027 * 5.25x
Free-Float
91.66%
Yield 2026 *
2.83%
Yield 2027 * 2.96%
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Compliance Officer 58 13/04/2025
Director TitleAgeSince
Director/Board Member 67 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
+2.32%+5.60%+49.90%+40.99% 358B
+1.25%+0.16%+36.27%+41.12% 293B
+1.30%-4.96%+9.63%+10.28% 247B
-0.73%+4.44%+42.22%+66.41% 219B
+3.95%-0.11%-0.87%-43.90% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average +1.03%-1.90%+32.26%+51.50% 399.14B
Weighted average by Cap. +0.76%-0.83%+41.25%+78.37%

Financials

2026 *2027 *
Net sales 57.58B 49.97B 46.79B 42.8B 80.81B 5,485B 81.86B 547B 215B 2,741B 216B 212B 9,122B 61.12B 53.04B 49.67B 45.43B 85.77B 5,823B 86.89B 581B 228B 2,909B 229B 225B 9,683B
Net income 13.78B 11.96B 11.2B 10.24B 19.34B 1,313B 19.59B 131B 51.41B 656B 51.74B 50.62B 2,183B 15.36B 13.33B 12.48B 11.42B 21.55B 1,463B 21.83B 146B 57.3B 731B 57.66B 56.41B 2,433B
Net Debt 33.11B 28.74B 26.91B 24.61B 46.47B 3,154B 47.08B 315B 124B 1,576B 124B 122B 5,246B 27.82B 24.14B 22.6B 20.68B 39.04B 2,650B 39.54B 264B 104B 1,324B 104B 102B 4,407B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA